SEARCH

SEARCH BY CITATION

References

  • 1
    Brennan FM, Maini RN, Feldmann M: TNFα—a pivotal role in rheumatoid arthritis? Br J Rheumatol 31: 293298, 1992
  • 2
    Maini RN, Elliott M, Brennan FM, Williams R, Chu CQ, Paleolog E, Charles PJ, Taylor PC, Feldmann M: Monoclonal anti-TNF-alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 144: 195223, 1995
  • 3
    Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 36: 16811690, 1993
  • 4
    Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 11051110, 1994
  • 5
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315324, 1988
  • 6
    Paulus HE, Egger MJ, Ward JR, Williams JH, and the Cooperative Systematic Studies of Rheumatic Diseases Group: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 33: 477484, 1990
  • 7
    Tak PP, van der Lubbe PA, Cauli A, Daha MR, Smeets TJM, Kluin PM, Meinders AE, Yanni G, Panayi GS, Breedveld FC: Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 38: 14571465, 1995
  • 8
    Tak PP, Thurkow EW, Daha MR, Kluin PM, Smeets TJM, Meinders AE, Breedveld FC: Expression of adhesion molecules in early rheumatoid synovial tissue. Clin Immunol Immunopathol 77: 236242, 1995
  • 9
    Van der Lubbe PA, Dijkmans BAC, Markusse HM, Nässander U, Breedveld FC: A randomized double-blind placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 38: 10971106, 1995
  • 10
    Philip R, Epstein LB: Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 323: 8689, 1986
  • 11
    Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D: Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 163: 13631375, 1986
  • 12
    Van Damme J, Opdenakker G, Simpson RJ, Rubira MR, Cayphas S, Vink A, Billiau A, van Snick J: Identification of the human 26-kD protein, interferon beta2 (IFN beta2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med 165: 914919, 1987
  • 13
    Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M: Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin 1 production in rheumatoid arthritis. Lancet ii: 244247, 1989
  • 14
    Haworth C, Brennan FM, Chantry D, Maini RN, Feldmann M: Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 21: 25752579, 1991
  • 15
    Chapman PT, Haskard DO: Leukocyte adhesion molecules. Br Med Bull 51: 296311, 1995
  • 16
    Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN: Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 39: 10821091, 1996
  • 17
    Issekutz AC, Meager A, Otterness I, Issekutz TB: The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leukocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin Exp Immunol 97: 2632, 1994